Below is a daily summary of links to the latest SPAC news and rumors gathered across the web.
Latest SPAC News: Ambipar buys Witt O’Briens for $161.5M, SPAC winter spreads to Middle East with two deals delayed, and Wag! partners with Babylist
Brazil’s Ambipar buys Witt O’Briens in $161.5 mln deal
Brazilian environmental services provider Ambipar said on Wednesday it bought Witt O’Briens for an enterprise value of $161.5 million, pushing ahead with its global expansion.
The deal, made through its subsidiary Ambipar Response, marks the company’s entry into Asia and Oceania markets and strengthens its presence in the continents where it already operates, Ambipar said in a securities filing.
SPAC Winter Spreads to Middle East With Two Deals Delayed
Concerns over the blank-check industry are spreading to the Middle East, dealing a blow to the region’s SPAC market that barely got off the ground.
Babylist and Wag! Join Forces To Help Pet Parents Welcome Baby Home
Babylist, the leading vertical marketplace and commerce destination for baby, and Wag! (Nasdaq: PET), a platform for busy pet parents, offering access to five-star dog walking, pet sitting, expert pet advice, wellness plans, and one-on-one training from a community of local pet caregivers, are helping new parents make the transition of bringing home a new baby a little easier.
READLevere SPAC’s Finance Chief Steps Down
Levere Holdings Corp. (NASDAQ:LVRA) said Tuesday that Stefan Krause, its chief financial officer and chief investment officer, intends to resign immediately.
The SPAC disclosed in a securities filing that Mr. Krause had given notice of his plans, and that the departure “was not a result of any disagreement with the company on any matter relating to its operations or its accounting or financial policies or procedures.”
READLanzaTech CEO Highlights Company Role as a Synthetic Biology Leader at White House Event Celebrating Biotechnology
LanzaTech NZ, Inc., an innovative Carbon Capture and Transformation company that transforms waste carbon into materials such as sustainable fuels, fabrics, packaging and other products that people use in their daily lives, today announced that Dr. Jennifer Holmgren, CEO of LanzaTech participated in the Summit on Biotechnology & Biomanufacturing for the American Bioeconomy today at The White House.
As previously announced LanzaTech has entered into a merger agreement for a business combination transaction with AMCI Acquisition Corp. II (Nasdaq: AMCI).
READ
AGBA (NASDAQ:AGBA) stock is up over +90% this morning following a +211% premarket spike on news it has signed a definitive agreement to combine with social streaming video platform Triller. AGBA, the company itself, was formed by the $555 million combination between a SPAC of the same name and TAG Companies, a financial services firm...
At the SPAC of Dawn Since closing its combination with DHC last month, AI customer engagement firm BEN (NASDAQ:BNAI) has rolled out new partnerships with call center and healthcare clients. And, while it faces a fair bit of competition in the chatbot realm, several high-profile institutions have demonstrated that creating one that provides useful services...
Blue Ocean (NASDAQ:BOCN) provided significantly more texture today in the presentation for its $275 million combination with Asian digital media group TNL Mediagene, which it expects to hit profitability in the second half of the year despite a slight shakeup in financing for the transaction. The first big update in the first investor deck is...
At the SPAC of Dawn A brand new market may have just opened up for space de-SPACs as NASA administrator Bill Nelson announced a shift in the agency’s $11 billion program for a mission to return samples from Mars. Rather than rely on the agency’s internal technologies that would be predicted to get a sample...
Overall deal flow between SPACs and biotech firms has slowed over the last year, but some pending FDA changes could breathe new life into particular business models within the space. In particular, the FDA has asked Congress as part of its 2025 Legislative Proposals to eliminate the interchangeability designation for biosimilar medications, claiming the existing...